Circular Genomics Unveils Its CircPATH™ Platform Following Landmark Nature Medicine Study Demonstrating Breakthrough Performance in Early Detection of Alzheimer's Disease

Data ReadoutpositiveCircPATH™Positive

AI Analysis

Summary

Circular Genomics unveiled its CircPATH™ platform following a landmark Nature Medicine study demonstrating breakthrough performance in early detection of Alzheimer's disease using blood-based circular RNA biomarkers validated across nearly 2,400 individuals. The assays outperform gold-standard tests and enable preclinical risk stratification years before symptom onset.

Clinical Trial Data

Primary Endpoint

Met

Patients

2,400

Outcome Details

Circular RNA biomarkers demonstrated breakthrough performance in early detection of Alzheimer's disease, outperforming gold-standard tests and enabling preclinical risk stratification years before symptom onset

Importance:7/10

Sentiment:

0.85

biomarkercircular RNAAlzheimer's diseaseearly detectionprecision medicineNature Medicinediagnostic

Related Companies

$DTIL $SHWZ

Read the original article

Published by PR Newswire Biotech on July 2, 2026 10:00 AM

Read Original